Papers/PMID:29522439
Resveratrol in Patients with Minimal Hepatic Encephalopathy.
Nutrients2018The record
2 findings · 1 compound · 2 endpoints
What it reported
How to read these marksWhat moved
2 findings
resveratrol — decreases alanine aminotransferase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“The comparison between RV group and placebo group shows a significant decrease in NH4 (p < 0.001) in AST (p < 0.001) and in ALT (p < 0.001) (Table 2).”
Quoted verbatim from Resveratrol in Patients with Minimal Hepatic Encephalopathy.. - Study
- RCT
- Duration
- 3 months
- Dose
- resveratrol pills 19.8 mg (Resvis) plus N-acetyl cysteine 600 mg and lactoferrin, versus placebo plus the same N-acetyl cysteine and lactoferrin, for 90 days
- Population
- Adults aged 25-65 with cirrhosis and minimal hepatic encephalopathy; N-acetyl cysteine 600 mg and lactoferrin given in both arms
Resveratrol in Patients with Minimal Hepatic Encephalopathy.2018PMID:29522439Permalink
resveratrol — decreases aspartate aminotransferase
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“The comparison between RV group and placebo group shows a significant decrease in NH4 (p < 0.001) in AST (p < 0.001) and in ALT (p < 0.001) (Table 2).”
Quoted verbatim from Resveratrol in Patients with Minimal Hepatic Encephalopathy.. - Study
- RCT
- Duration
- 3 months
- Dose
- resveratrol pills 19.8 mg (Resvis) plus N-acetyl cysteine 600 mg and lactoferrin, versus placebo plus the same N-acetyl cysteine and lactoferrin, for 90 days
- Population
- Adults aged 25-65 with cirrhosis and minimal hepatic encephalopathy; N-acetyl cysteine 600 mg and lactoferrin given in both arms
Resveratrol in Patients with Minimal Hepatic Encephalopathy.2018PMID:29522439Permalink